Caffeine inhibits cell proliferation and regulates PKA/GSK3β pathways in U87MG human glioma cells

Bo Mi Ku1, Yeon Kyung Lee, Joo Yeon Jeong

  • 1Department of Anatomy and Neurobiology, Institute of Health Science, School of Medicine, Gyeongsang National University, Jinju, 660-751, Korea.

Molecules and Cells
|January 14, 2011
PubMed

Insights

Caffeine demonstrates anti-cancer effects against gliomas by halting cell cycle progression and triggering programmed cell death (apoptosis). These findings support caffeine

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Caffeine is a widely consumed methylxanthine with known anti-cancer properties.
  • Gliomas are aggressive brain tumors with limited treatment options.

Purpose of the Study:

  • To investigate the anti-cancer effects of caffeine on glioma cells.
  • To elucidate the molecular mechanisms underlying caffeine's action on gliomas.

Main Methods:

  • In vitro studies using glioma cell lines to assess proliferation, cell cycle arrest, and apoptosis.
  • In vivo studies in animal models to evaluate tumor growth and apoptosis.
  • Western blot analysis to examine protein phosphorylation, including GSK3β.
  • Inhibition studies using H89 (a PKA inhibitor) to explore signaling pathways.

Main Results:

  • Caffeine inhibited glioma cell proliferation by inducing G(0)/G(1) cell cycle arrest via suppression of Rb phosphorylation.
  • Caffeine triggered apoptosis through caspase-3 activation and PARP cleavage.
  • Caffeine induced phosphorylation of GSK3β(ser9), potentially involving a cAMP-dependent PKA pathway.
  • In vivo, caffeine reduced tumor proliferation and increased apoptosis.

Conclusions:

  • Caffeine effectively reduces glioma cell proliferation and induces apoptosis.
  • The anti-cancer effects of caffeine involve cell cycle arrest and caspase-dependent cell death.
  • Caffeine presents a potential therapeutic option for malignant gliomas.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...